Huge trial on our core work, catch-up here
The CONVINCE Visual Abstract
Check out the COVINCE-ing Visual Abstract by Saumya Vishnoi
This week, NephJC will discuss whether obinutuzumab is ready to outperform tacrolimus in primary membranous nephropathy
In this edition of NephJC, we discuss the largest case series of kidney biopsies in patients with Diabetes.
This week we will discuss whether a bundled, team-based hypertension intervention- featuring intensive BP targets, home monitoring, health coaching, and audit feedback- can overcome poverty, clinical inertia, and fragmented care to improve blood pressure control in low-income patients receiving care at federally qualified health centers.
This week, we will discuss a phase 2 trial of the TRPC6 inhibitor BI 764198 in FSGS—an early signal for a podocyte-targeted therapy showing proteinuria reduction but set against small numbers, heterogeneity, and methodological trade-offs that frame this as direction-finding rather than definitive evidence.
Huge trial on our core work, catch-up here
Welcome to #TenTweetNephJC
— Nephrology Journal Club (@NephJC) July 31, 2023
✳️10 tweets #NephJC catch-up ✳️
🌟Let’s recap the CONVINCE trial which pitted HDF against HD
🌟Do we now have CONVINCE-ing evidence for the superiority of convection added to diffusion? pic.twitter.com/92gW0zKv76
Check out the COVINCE-ing Visual Abstract by Saumya Vishnoi